Nov 19, 2026 | Press Releases
Strengthens scientific, regulatory, and government partnership capabilities Dr. Balboni will advise on Valion Bio’s scientific strategy to advance medical countermeasures and pursue government and industry partnerships SAN ANTONIO, TX / ACCESS Newswire /...
Nov 17, 2026 | Press Releases
Production run achieved approximately 27% higher productivity compared with historical manufacturing data while meeting all predefined drug substance acceptance criteria SAN ANTONIO, TX / ACCESS Newswire / November 17, 2026 / Valion Bio, Inc. (NASDAQ:VBIO)...
Nov 11, 2026 | Press Releases
Top-line results from fully NIAID-funded Entolimod efficacy study expected in early December SAN ANTONIO, TX / ACCESS Newswire / November 11, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical...
Oct 30, 2026 | Press Releases
NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive safety findingsFully funded study will evaluate Entolimod’s potential to improve survival rates and...
Oct 28, 2026 | Press Releases
AFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a planned, fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure SAN ANTONIO, TX /...